Table 1 Patient characteristics
From: Effect of disease duration on fecal biomarkers in ulcerative colitis: a prospective cohort study
Characteristics | All N = 128 |
|---|---|
Age (year), median (IQR) | 48 (36–61) |
Male/Female, n (%) | 77 (60.2)/51 (39.8) |
Disease duration (year), median (IQR) | 8 (4–17) |
 Disease extent, n (%) |  |
 Extensive colitis | 77 (60.2) |
 Left-sided colitis | 40 (31.2) |
 Proctitis | 11 (8.6) |
CAI (Rachmilewitz index), median (IQR) | 1 (0–3) |
MES, n (%) | Â |
 MES 0 | 51 (39.8) |
 MES 1 | 45 (35.2) |
 MES 2 | 30 (23.4) |
 MES 3 | 2 (1.6) |
UCEIS, median (IQR) | 1 (0–3) |
Sum of MES, median (IQR) | 1 (0–3) |
FC (µg/g), median (IQR) | 421 (76–3408) |
FIT (ng/mL), median (IQR) | 50 (30–1026) |
Medication at study, n (%) | Â |
 Oral 5-ASA | 88 (68.8) |
 Suppository steroids | 7 (5.5) |
 Systemic steroids | 13 (10.2) |
 Immunomodulators | 35 (27.3) |
 Advanced therapy | 47 (36.7) |